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Abstract
Purpose Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast 
cancer.
Methods Postmenopausal women with HR+ , HER2− advanced breast cancer and no prior systemic therapy for advanced 
disease were enrolled in the Phase III MONALEESA-2 trial (NCT01958021). Patients were randomized to ribociclib 
(600 mg/day; 3 weeks-on/1 week-off) plus letrozole (2.5 mg/day; continuous) or placebo plus letrozole until disease progres-
sion, unacceptable toxicity, death, or treatment discontinuation. The primary endpoint was investigator-assessed progression-
free survival; predefined subgroup analysis evaluated progression-free survival in patients with de novo advanced breast 
cancer. Secondary endpoints included safety and overall response rate.
Results Six hundred and sixty-eight patients were enrolled, of whom 227 patients (34%; ribociclib plus letrozole vs placebo 
plus letrozole arm: n = 114 vs. n = 113) presented with de novo advanced breast cancer. Median progression-free survival 
was not reached in the ribociclib plus letrozole arm versus 16.4 months in the placebo plus letrozole arm in patients with de 
novo advanced breast cancer (hazard ratio 0.45, 95% confidence interval 0.27–0.75). The most common Grade 3/4 adverse 
events were neutropenia and leukopenia; incidence rates were similar to those observed in the full MONALEESA-2 popu-
lation. Ribociclib dose interruptions and reductions in patients with de novo disease occurred at similar frequencies to the 
overall study population.
Conclusions Ribociclib plus letrozole improved progression-free survival vs placebo plus letrozole and was well tolerated 
in postmenopausal women with HR+, HER2− de novo advanced breast cancer.
Keywords Breast cancer · CDK inhibitor · Ribociclib · Endocrine therapy · De novo advanced breast cancer · Hormone 
receptor-positive
Introduction
Breast cancer diagnoses account for 25% of all newly diag-
nosed female cancer cases per year, affecting an estimated 
1.7 million people worldwide [1]. The most common breast 
cancer subtype is hormone receptor-positive (HR+) disease, 
which constitutes 75% of all breast cancers [2]. Around 
3–25% of newly diagnosed patients present with de novo 
HR+ advanced breast cancer [3, 4]. Patients are classed as 
having de novo advanced breast cancer if they present with 
advanced disease without having a previous diagnosis at an 
earlier stage of breast cancer; this excludes patients who 
have received prior therapy and relapsed. Current guide-
lines recommend the use of first-line endocrine therapy, with 
or without a cyclin-dependent kinase (CDK) 4/6 inhibitor, 
in patients with de novo or relapsed HR+ advanced breast 
cancer [5–8]. Due to a lack of exposure to systemic treat-
ment, inherent differences may exist in the tumor biology 
of therapy-naïve de novo breast cancer compared with 
relapsed breast cancer [9], potentially contributing to the 
better prognosis of the de novo patient population [10]. The 
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differences in clinical outcomes observed between patients 
with de novo and relapsed advanced breast cancer highlight 
the need to assess novel therapy options in this patient popu-
lation [10–12].
The cyclin D–CDK4/6–inhibitor of CDK4 (INK4)–ret-
inoblastoma (Rb) pathway is frequently disrupted in HR+ 
breast cancer [13], and has been associated with a poor 
clinical outcome and resistance to endocrine therapy [14]. 
Targeting the cyclin D–CDK4/6–INK4–Rb pathway may, 
therefore, present an effective strategy to enhance the efficacy 
of endocrine therapies. Ribociclib is an orally bioavailable, 
selective inhibitor of CDK4/6 [15]. Results from the Phase 
III MONALEESA-2 (NCT01958021) planned interim analy-
sis demonstrated that the addition of ribociclib to letrozole 
significantly improved progression-free survival compared 
with placebo plus letrozole in patients with HR+, human epi-
dermal growth factor receptor 2-negative (HER2−) advanced 
breast cancer, with a hazard ratio of 0.56 (p < 0.001) [16]. 
Treatment with ribociclib plus letrozole was associated with 
a rapid response; 76% of patients with evaluable measur-
able disease had a reduction in tumor size following 8 weeks 
of treatment [17]. Here we report efficacy and safety results 
from a prospective subgroup analysis of MONALEESA-2 in 
patients with de novo advanced breast cancer.
Methods
Study design and participants
MONALEESA-2 is a Phase III, randomized, double-blind, 
placebo-controlled trial that enrolled postmenopausal 
women with HR+, HER2− advanced breast cancer. Full 
details of the study design have been published previously 
[16]. Briefly, patients were required to have measurable dis-
ease with at least one measurable lesion as per Response 
Evaluation Criteria In Solid Tumors (RECIST) v1.1 [18] 
or at least one predominantly lytic bone lesion. All patients 
had an Eastern Cooperative Oncology Group (ECOG) per-
formance status of 0 or 1. Patients were excluded if they had 
inflammatory breast cancer, central nervous system metas-
tases, cardiac disease or Fridericia’s corrected QT interval 
(QTcF) > 450 ms, or impairment of gastrointestinal func-
tion that would have altered study drug absorption. Patients 
must not have received prior systemic therapy for advanced 
disease, except for ≤ 14 days of letrozole or anastrozole. The 
use of concomitant medications with known risk of prolong-
ing the QT interval or inducing Torsades de Pointes was 
prohibited.
This study was conducted in accordance with Good Clini-
cal Practice guidelines and the Declaration of Helsinki. An 
independent ethics committee and institutional review 
boards approved the study protocol and any subsequent 
amendments at each participating center. A study steering 
committee monitored study conduct in line with the pro-
tocol. Written informed consent was obtained from all the 
patients.
Randomization
MONALEESA-2 patients from 223 centers in 29 countries 
were randomized 1:1 to receive oral ribociclib in combina-
tion with letrozole or placebo plus letrozole. Randomization 
was stratified according to the presence of liver and/or lung 
metastases. Screening and treatment allocation was per-
formed using an interactive voice and web response system. 
Patients and investigators were blinded to the assigned treat-
ment; both ribociclib and placebo were identical in label, 
packaging, appearance, and administration schedule. Treat-
ment crossover from placebo to ribociclib was not permitted.
Treatment and procedures
Patients received oral ribociclib (600 mg/day, 3 weeks-
on/1 week-off schedule, in 28-day treatment cycles) in 
combination with letrozole (2.5 mg/day, continuously) 
or placebo plus letrozole until disease progression, unac-
ceptable toxicity, death, or discontinuation for any other 
reason. Ribociclib dose adjustments including dose inter-
ruption, reduction, and permanent discontinuation were 
permitted for the management of adverse events. Dose 
modifications of letrozole were not permitted.
Tumor response was assessed locally according to 
RECIST v1.1 [18]. Computed tomography/magnetic res-
onance imaging assessments were conducted at screen-
ing, then every 8  weeks for the first 18  months, and 
every 12 weeks thereafter. A whole-body bone scan was 
performed at baseline. Cardiac function was monitored 
by triplicate electrocardiograms (ECGs) performed at 
screening, day 15 of cycle 1, and day 1 of cycles 2–3 in 
all patients; following a protocol amendment, additional 
ECG assessments were performed on day 1 of cycles 4–9 
in all patients, and on day 1 of all subsequent cycles in 
patients who experienced a mean QTcF ≥ 481 ms prior 
to cycle 10. Centralized laboratory assessments includ-
ing hematology and biochemistry panels were carried 
out at screening, cycle 1 day 15, and day 1 of all sub-
sequent cycles; additional laboratory data were collected 
periodically throughout treatment. Adverse events were 
characterized throughout the study and graded according 
to the Common Terminology Criteria for Adverse Events 
(CTCAE) v4.03 [19].
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Outcomes
The primary objective was to compare progression-free 
survival between the two treatment arms per local investi-
gator assessment. Overall survival was the key secondary 
endpoint. Additional secondary endpoints included overall 
response rate, clinical benefit rate, safety, and tolerability.
Statistical analysis
This was a prespecified exploratory subgroup analysis. 
To compare the primary endpoint of progression-free sur-
vival between the treatment arms in the full study popula-
tion, a log-rank test stratified according to the presence 
or absence of liver or lung metastases was utilized [16]. 
A stratified Cox regression analysis was used to estimate 
the hazard ratio and 95% confidence intervals of progres-
sion-free survival [16]. The subgroup analysis, including 
Kaplan–Meier estimates and treatment effect hazard ratio 
estimates using an unstratified Cox regression model, 
was performed in patients with de novo disease. Efficacy 
analyses were performed in the intent-to-treat population 
and safety analyses were performed in all patients who 
received at least one dose of study treatment and had at 
least one post-baseline safety assessment.
Results
Patient and disease characteristics
From January 24, 2014 to March 24, 2015, 668 patients were 
randomized to the ribociclib plus letrozole (n = 334) and pla-
cebo plus letrozole (n = 334) arms. Among all patients rand-
omized, 227 (34%) presented with de novo advanced breast 
cancer at diagnosis; these patients were compared between 
treatment arms in this exploratory analysis. There was an 
even distribution of patients with de novo disease across 
both treatment arms; 114 (34%) patients in the ribociclib 
plus letrozole arm and 113 (34%) patients in the placebo plus 
letrozole arm (Table 1). Baseline characteristics of patients 
with de novo advanced breast cancer were well balanced 
across both treatment arms, except for ECOG performance 
status. A higher proportion of patients in the ribociclib plus 
letrozole arm (66%) had an ECOG performance status of 0, 
compared with 54% of patients in the placebo plus letrozole 
arm.
Treatment
At the interim analysis data cut-off (January 29, 2016), fewer 
patients with de novo disease in the ribociclib plus letrozole 
arm had discontinued treatment compared with those receiv-
ing placebo plus letrozole (30% vs. 43%, respectively). The 
most common reason for treatment discontinuation was 
disease progression in both arms (Fig. 1). Patients in the 
ribociclib plus letrozole arm had a longer median duration 
of exposure to study treatment than patients who received 
placebo plus letrozole (14.1 and 12.8 months, respectively). 
The median relative dose intensity for ribociclib was 88% 
and the median relative dose intensity for letrozole was 
100% for both treatment arms.
Efficacy
The combination of ribociclib plus letrozole prolonged pro-
gression-free survival compared with placebo plus letrozole 
in patients with de novo advanced breast cancer, with a haz-
ard ratio of 0.45 (95% CI 0.27–0.75). Median progression-
free survival in the ribociclib plus letrozole arm was not 
reached versus 16.4 months in the placebo plus letrozole arm 
(Fig. 2). After 12 months, the estimated progression-free 
survival rates in the ribociclib plus letrozole versus placebo 
plus letrozole arms were 82% versus 66%, respectively. The 
overall response rates in the intent-to-treat population were 
47% in the ribociclib plus letrozole arm versus 34% in the 
placebo plus letrozole arm; clinical benefit rates were 83% 
versus 77% (Table 2). In patients with measurable disease 
at baseline, the overall response rates were 56% versus 45% 
and the clinical benefit rates were 82% versus 77% in the 
ribociclib plus letrozole versus placebo plus letrozole arms, 
respectively. Overall survival results were immature at the 
time of this interim analysis.
Safety and tolerability
Overall, the safety profile of ribociclib plus letrozole in 
patients with de novo advanced breast cancer was similar to 
that observed in the full MONALEESA-2 study population 
[16]. In the de novo subset, there was a similar incidence of 
all-grade adverse events of any causality in the ribociclib 
plus letrozole vs placebo plus letrozole treatment arms (97% 
vs. 97%). Neutropenia, nausea, and fatigue were the most 
common adverse events in the ribociclib plus letrozole arm 
(Table 3). The incidence of non-hematologic adverse events 
of nausea, fatigue, alopecia, vomiting, rash, pyrexia, elevated 
aspartate aminotransferase, and elevated alanine aminotrans-
ferase was increased by > 10% in the ribociclib plus letro-
zole arm compared with the placebo plus letrozole arm.
There was a higher incidence of Grade 3/4 adverse events 
in the ribociclib plus letrozole arm (77%) compared with the 
placebo plus letrozole arm (31%). The most common Grade 
3/4 adverse events (≥ 15%) in the ribociclib plus letrozole 
arm were neutropenia (55%) and leukopenia (21%). Febrile 
neutropenia rates were low, occurring in 2 (2%) versus 0 
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patients with de novo disease treated with ribociclib plus 
letrozole vs placebo plus letrozole. QTcF prolongation 
> 500 ms was not reported in any patients with de novo dis-
ease in either treatment arm. Adverse events were the most 
common reason for dose interruptions and reductions. At 
least one dose interruption due to an adverse event occurred 
in 75 (66%) patients in the ribociclib plus letrozole arm and 
17 (15%) patients in the placebo plus letrozole arm. At least 
one dose reduction due to an adverse event occurred in 55 
(48%) patients in the ribociclib plus letrozole arm and 6 (5%) 
patients in the placebo plus letrozole arm. Neutropenia was 
the most frequent adverse event requiring ribociclib dose 
interruption or dose reduction (56 [49%] patients).
Discussion
This predefined subgroup analysis of the MONALEESA-2 
trial demonstrates that postmenopausal women with de novo 
HR+, HER2− advanced breast cancer at diagnosis who 
received ribociclib in combination with letrozole had pro-
longed progression-free survival compared with those who 
received placebo plus letrozole, with an approximate 55% 
reduction in the risk of progression (hazard ratio 0.45, 95% 
CI 0.27–0.75). Median progression-free survival was not 
reached in the ribociclib plus letrozole arm, compared with 
16.4 months in the placebo plus letrozole arm. Progression-
free survival benefit with the addition of ribociclib to letrozole 
was consistent with that observed in the MONALEESA-2 
intent-to-treat population, where a hazard ratio of 0.56 (95% 
CI 0.43–0.72, p < 0.001) was observed [16]. Ribociclib plus 
letrozole was also associated with improved overall response 
and clinical benefit rates versus placebo plus letrozole in 
patients with de novo disease.
Enhanced treatment benefits in patients with de novo 
advanced disease have previously been described with the 
CDK4/6 inhibitor palbociclib in combination with letrozole 
in the PALOMA-2 trial [20]. The FALCON study recently 
Table 1  Baseline patient 
characteristics
ECOG Eastern Cooperative Oncology Group, HER2− human epidermal growth factor receptor 2-negative, 
HR+ hormone receptor-positive
a Includes liver, lung, and other visceral metastases
Characteristic Patients with de novo advanced HR+, HER2− breast 
cancer
n = 227
Ribociclib + letrozole
(n = 114)
Placebo + letrozole
(n = 113)
Age, median (range), years 62.5 (37.0–82.0) 63.0 (29.0–88.0)
Race, n (%)
 Caucasian 90 (79) 91 (81)
 Asian 10 (9) 11 (10)
 Black 6 (5) 4 (4)
 Other/unknown 8 (7) 7 (6)
ECOG performance status, n (%)
 0 75 (66) 61 (54)
 1 39 (34) 52 (46)
Disease stage at study entry, n (%)
 III 1 (1) 1 (1)
 IV 113 (99) 112 (99)
Number of metastatic sites, n (%)
 0 1 (1) 0
 1 33 (29) 36 (32)
 2 37 (32) 38 (34)
 ≥ 3 43 (38) 39 (35)
Site of metastases, n (%)
 Breast 7 (6) 9 (8)
 Bone 88 (77) 85 (75)
 Bone only 28 (25) 24 (21)
 Viscerala 53 (46) 55 (49)
 Lymph nodes 61 (54) 56 (50)
 Other 15 (13) 8 (7)
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reported improved efficacy for first-line fulvestrant over 
anastrozole, with a hazard ratio of 0.80 (95% CI 0.64–0.99) 
in a largely de novo patient population [21]. Median pro-
gression-free survival was 16.6 months in patients who 
received fulvestrant therapy compared with 13.8 months in 
the anastrozole arm; both values are in line with the median 
progression-free survival of 16.4 months reported herein 
for placebo plus letrozole-treated patients with de novo 
advanced disease.
Fig. 1  MONALEESA-2 trial 
profile (CONSORT diagram)
290 excluded
114 included in intent-to-treat de novo 
• 114 included in safety set
• 21 due to disease progression
• 6 due to adverse events
•
• 3 due to physician decision
•
• 1 due to death
334 randomized to ribociclib + letrozole
• 334 received treatment
334 randomized to placebo + letrozole
• 330 received treatment
• 4 did not receive treatment
668 randomized
958 screened
114 de novo de novo 113
• 1 did not receive treatment
• 41 due to disease progression
• 3 due to adverse events
•
• 2 due to physician decision
• 3 due to death
113 included in intent-to-treat de novo 
• 112 included in safety set
Fig. 2  Kaplan–Meier analysis 
of locally assessed progression-
free survival in patients with de 
novo advanced breast cancer in 
the MONALEESA-2 trial.  
CI confidence interval
114 106 100 92 87 87 66 50 29 5 1 0
113 99 93 85 81 70 52 32 16 7 3 0
No. at risk
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Placebo + letrozole
Ribociclib + letrozole
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Events, no. (%) 22 (19) 42 (37)
(95% CI)
      0.45 
(0.27–0.75)
Progression-free survival rate, % (95% CI)
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12-month 82 (73–88) 66 (55–74)
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CDK4/6 inhibitor combinations have demonstrated sig-
nificantly extended progression-free survival in patients 
who received no prior systemic therapy for advanced dis-
ease in the MONALEESA-2 [16] and PALOMA-2 [22] 
trials, highlighting the utility of this treatment strategy 
in the first-line setting for advanced HR+, HER2− breast 
cancer. Recent data have also shown promising results for 
CDK4/6 inhibitor-based regimens in patients with HR+, 
HER2− breast cancer who received prior single-agent 
endocrine therapy. Abemaciclib in combination with ful-
vestrant extended progression-free survival compared with 
fulvestrant monotherapy, [23] and palbociclib plus fulves-
trant also improved progression-free survival compared 
with fulvestrant plus placebo [24]. Data from these studies 
demonstrate the potential for CDK4/6 inhibitor-based com-
binations as second-line therapies for patients with advanced 
HR+, HER2− breast cancer who have received prior sin-
gle-agent endocrine therapy. Further research is required 
to determine the optimal treatment sequence for CDK4/6 
inhibitors in advanced HR+, HER2− breast cancer, particu-
larly since current data in the second-line setting are from 
patients who have received no prior CDK4/6 inhibitor-based 
therapy. Final overall survival analyses are needed to deter-
mine whether a potential long-term benefit is observed with 
the addition of a CDK4/6 inhibitor to first-line endocrine 
therapy, and results are eagerly awaited.
The adverse events associated with the combina-
tion of ribociclib plus letrozole in patients with de novo 
Table 2  Summary of best overall response per RECIST v1.1
BOR best overall response, CBR clinical benefit rate, CI confidence 
interval, CR complete response, HER2− human epidermal growth 
factor receptor 2-negative, HR+ hormone receptor-positive, NCRNPD 
neither complete response nor progressive disease (for non-measur-
able disease at baseline), ORR overall response rate, PD progressive 
disease, PR partial response, SD stable disease
a CR + PR
b CR + PR + (SD + NCRNPD ≥ 24 weeks)
Patients with de novo advanced HR+, 
HER2− breast cancer
n = 227
Ribociclib + letrozole Placebo + letrozole
All patients, n 114 113
Confirmed BOR, n (%)
 CR 2 (2) 1 (1)
 PR 52 (46) 37 (33)
 SD 36 (32) 34 (30)
 NCRNPD 16 (14) 26 (23)
 PD 3 (3) 9 (8)
 Unknown 5 (4) 6 (5)
ORRa, n (%)
[95% CI]
54 (47)
[38–57]
38 (34)
[25–42]
CBRb, n (%)
[95% CI]
95 (83)
[77–90]
87 (77)
[69–85]
Patients with  
measurable disease  
at baseline, n
96 83
Confirmed BOR, n (%)
 CR 2 (2) 0
 PR 52 (54) 37 (45)
 SD 36 (38) 34 (41)
 PD 2 (2) 8 (10)
 Unknown 4 (4) 4 (5)
ORRa, n (%)
[95% CI]
54 (56)
[46–66]
37 (45)
[34–55]
CBRb, n (%)
[95% CI]
79 (82)
[75–90]
64 (77)
[68–86]
Table 3  Adverse events (any grade; ≥ 15% in either arm), regardless 
of relationship to study drug
AST aspartate aminotransferase, HER2− human epidermal growth 
factor receptor 2-negative, HR+ hormone receptor-positive
a One patient in the placebo plus letrozole arm was randomized but 
did not receive study treatment
b Includes neutropenia, neutrophil count decreased, and granulocyto-
penia
c Includes leukopenia and white blood cell count decreased
d Includes anemia, hemoglobin decreased, and anemia macrocytic
e Includes rash and rash maculopapular
n (%) Patients with de novo advanced HR+, HER2− 
breast cancer
n = 226
Ribociclib + letrozole
(n = 114)
Placebo + letrozole
(n = 112a)
Grade All grade Grade 3/4 All grade Grade 3/4
Any adverse event 111 (97) 88 (77) 109 (97) 35 (31)
 Neutropeniab 80 (70) 63 (55) 5 (4) 1 (1)
 Nausea 55 (48) 1 (1) 29 (26) 0
 Fatigue 48 (42) 1 (1) 30 (27) 1 (1)
 Alopecia 45 (39) – 17 (15) –
 Leukopeniac 36 (32) 24 (21) 0 0
 Diarrhea 32 (28) 2 (2) 24 (21) 0
 Vomiting 29 (25) 2 (2) 17 (15) 0
 Anemiad 28 (25) 2 (2) 4 (4) 3 (3)
 Rashe 27 (24) 2 (2) 11 (10) 0
 Arthralgia 25 (22) 0 37 (33) 0
 Back pain 25 (22) 1 (1) 22 (20) 0
 Headache 25 (22) 1 (1) 24 (21) 0
 Constipation 24 (21) 1 (1) 18 (16) 0
 Hot flush 24 (21) 0 27 (24) 0
 Decreased appetite 22 (19) 2 (2) 21 (19) 1 (1)
 Hypertension 20 (18) 15 (13) 16 (14) 13 (12)
 Pyrexia 20 (18) 1 (1) 6 (5) 0
 AST increased 19 (17) 7 (6) 4 (4) 0
 Cough 17 (15) 0 19 (17) 0
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disease were consistent with those observed in the overall 
MONALEESA-2 study population [16] and the safety profile 
of other CDK4/6 inhibitors [22, 24]. The hematologic toxici-
ties of neutropenia, leukopenia, and anemia were among the 
most frequent adverse events in the ribociclib plus letrozole 
arm, consistent with the known on-target effect of CDK4/6 
inhibitors on hematologic precursors in the bone marrow 
[25]. Grade 3/4 neutropenia was common in patients with 
de novo disease-receiving ribociclib; however, the condition 
was rapidly reversible upon dose reduction or interruption.
In conclusion, combining ribociclib with letrozole pro-
vided clinically meaningful improvements in progression-
free survival, overall response rates, and clinical ben-
efit rates and was well tolerated in patients with de novo 
advanced HR+, HER2− breast cancer. Results from this 
subgroup analysis of the MONALEESA-2 trial demonstrate 
that ribociclib plus letrozole provides a valuable first-line 
therapy option for women who present with de novo HR+, 
HER2− advanced breast cancer at diagnosis.
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